Enveda Secures $311 Million in Series E Funding

Enveda has raised $311 million in Series E funding, bringing its valuation to $2 billion, a doubling in just 12 months since its last funding round. Founded in 2019 by Viswa Colluru, Enveda focuses on AI-driven drug discovery, emphasizing the potential of harnessing powerful medicines from plants and microbes instead of traditional lab synthesis. Catalio Capital Management led the funding round, with participation from Iconiq.

Currently, Enveda is testing several drugs in patients, marking its position among the companies advancing AI-discovered candidates into human clinical trials. Notably, Enveda points out that AI has yet to produce any FDA-approved drugs, highlighting the challenges in the field. This funding will likely enhance Enveda's capabilities in bringing nature-derived drugs to market, impacting the landscape of AI drug discovery significantly.